MedPath

Study to Evaluate the Safety and Efficacy of Levetiracetam in Comparison To Magnesium Sulphate in the Management of Severe Pre â?? Eclampsia

Not Applicable
Completed
Conditions
Health Condition 1: O141- Severe pre-eclampsia
Registration Number
CTRI/2020/02/023194
Lead Sponsor
BLDE Deemed to be University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1.All pregnant women with gestational age above 28 weeks presenting with features of severe pre eclampsia and imminent eclampsia during the period will be recruited into the study

2.Patients giving informed and written consent for investigations

Exclusion Criteria

1.Patients who were diagnosed with other causes of convulsions in pregnancy like cerebral malaria and epilepsy

2.Chronic hypertensive pregnant females

3.Pregnant females with fetal anomalies detected on USG

4.Patients who withdraw the consent for further participation in the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the efficacy of Levetiracetam as an alternative to Magnesium sulphate in the prevention of convulsions in severe preeclampsia and imminent eclampsia. <br/ ><br>To evaluate the neonatal outcomes in babies exposed to levetiracetam and magnesium sulphate <br/ ><br>Timepoint: 1.Adverse effects st the time of administration <br/ ><br>2. Occurence of seizures inspite of giving the drug <br/ ><br>3. adverse effects of the drug at 24 hours <br/ ><br>4 Adverse effects of drugs between 24 hours to 7 days after the administration <br/ ><br>5. advesre effect of the drug at birth on the neonate <br/ ><br>6. Adverse effect of the drug between 24 hours to 7 days after administration of the drug on the neonate
Secondary Outcome Measures
NameTimeMethod
To study the perinatal outcoe after the exposure to the drugsTimepoint: adverse effect of the drug on the neonate at 1 month after the delivery
© Copyright 2025. All Rights Reserved by MedPath